BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 34885993)

  • 1. The Development of BTK Inhibitors: A Five-Year Update.
    Tasso B; Spallarossa A; Russo E; Brullo C
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases.
    Zhang D; Gong H; Meng F
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
    Brullo C; Villa C; Tasso B; Russo E; Spallarossa A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Bruton's tyrosine kinase in the immune system and disease.
    McDonald C; Xanthopoulos C; Kostareli E
    Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
    Feng Y; Duan W; Cu X; Liang C; Xin M
    Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
    Das D; Wang J; Hong J
    Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Fast and Clean BTK Inhibitor.
    Gabizon R; London N
    J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J; Chen C; Wang D; Zhang J; Zhang T
    Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
    Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
    Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
    Rip J; Van Der Ploeg EK; Hendriks RW; Corneth OBJ
    Crit Rev Immunol; 2018; 38(1):17-62. PubMed ID: 29717662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
    Sakthivel S; Habeeb SKM
    J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orelabrutinib: First Approval.
    Dhillon S
    Drugs; 2021 Mar; 81(4):503-507. PubMed ID: 33704654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
    Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY
    Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
    Neys SFH; Rip J; Hendriks RW; Corneth OBJ
    Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.
    Hopkins BT; Bame E; Bell N; Bohnert T; Bowden-Verhoek JK; Bui M; Cancilla MT; Conlon P; Cullen P; Erlanson DA; Fan J; Fuchs-Knotts T; Hansen S; Heumann S; Jenkins TJ; Marcotte D; McDowell B; Mertsching E; Negrou E; Otipoby KL; Poreci U; Romanowski MJ; Scott D; Silvian L; Yang W; Zhong M
    Bioorg Med Chem; 2019 Jul; 27(13):2905-2913. PubMed ID: 31138459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.